×
About 510 results

ALLMedicine™ Membranoproliferative Glomerulonephritis Center

Research & Reviews  197 results

Bilateral macular drusen in acquired partial lipodystrophy with type 2 membranoprolifer...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217924
BMJ Case Reports; Tanner A, Chan HW et. al.

Jun 23rd, 2021 - A 35-year-old woman with acquired partial lipodystrophy (PLD) and features of type 2 membranoproliferative glomerulonephritis (MPGN-II), presented with difficulty in her fine detailed vision over the past year. She had right amblyopia from a hyper...

Membranous nephropathy associated with multicentric Castleman's disease that was succes...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191014
BMC Nephrology; Saiki R, Katayama K et. al.

Jun 11th, 2021 - Multicentric Castleman's disease is a life-threatening disorder involving a systemic inflammatory response and multiple organ failure caused by the overproduction of interleukin-6. Although renal complications of Castleman's disease include AA amy...

Recurrent glomerulonephritis after kidney transplantation: a practical approach.
https://doi.org/10.1097/MOT.0000000000000887
Current Opinion in Organ Transplantation; De Souza L, Prunster J et. al.

May 28th, 2021 - This review will provide a practical approach in the assessment of kidney failure patients with primary glomerulonephritides (GN) being considered for kidney transplantation, focusing on high-risk subtypes of immunoglobulin A nephropathy, focal se...

A clinical approach to children with C3 glomerulopathy.
https://doi.org/10.1007/s00467-021-05088-7 10.1038/nrneph.2017.37 10.1016/j.ekir.2020.02.1033 10.1681/ASN.2014101000 10.1681/ASN.2019080851 10.3389/fimmu.2019.02166 10.1111/imr.12468 10.1093/ndt/13.8.1984 10.1681/ASN.2005090923 10.1016/j.semnephrol.2013.08.004 10.1016/j.kint.2016.05.011 10.1038/s41581-018-0107-2 10.1016/j.kint.2016.10.005 10.1681/ASN.2015101155 10.2215/CJN.02790313 10.2353/ajpath.2007.060573 10.4049/jimmunol.170.3.1517 10.1038/ni.2499 10.1681/ASN.2016111179 10.1056/NEJMoa2023386 10.1152/ajprenal.2001.281.5.F841 10.1038/ng912 10.2215/CJN.09541010 10.1681/ASN.2015040385 10.1172/JCI71866 10.1016/S0140-6736(10)60670-8 10.1681/ASN.2012020166 10.1038/ki.2013.348 10.1172/JCI68280 10.3389/fimmu.2019.00886 10.1007/s00467-006-0299-8 10.1038/modpathol.3800773 10.1136/jmg.2006.045328 10.1038/ki.2008.657 10.1038/ki.2013.377 10.1007/s00467-020-04799-7 10.1007/s00467-020-04736-8 10.1016/j.molimm.2016.01.010 10.1053/j.ajkd.2018.09.002 10.1681/ASN.2017030258 10.1038/ki.2012.63 10.1681/ASN.2014040406 10.1111/his.13385 10.1016/j.nefro.2016.05.011 10.1016/j.ekir.2019.02.006 10.2215/CJN.04700513 10.2215/CJN.01820214 10.1007/s00467-018-3989-0 10.1186/s13023-019-1237-8 10.1016/j.kint.2017.04.017 10.4049/jimmunol.1402770 10.1016/j.molimm.2012.05.009 10.1056/NEJMc1107484 10.1016/j.imbio.2016.06.008 10.1038/sj.ki.5000269 10.1093/ndt/gfv054 10.1172/JCI43343 10.1038/ki.2015.227 10.2215/CJN.15241219 10.2215/CJN.12901211 10.1007/s00467-013-2503-y 10.1053/j.ajkd.2014.09.025 10.1053/j.ajkd.2017.11.019 10.2215/CJN.01360215 10.1053/j.ajkd.2018.12.046 10.1186/s12882-017-0802-4 10.1182/blood-2017-05-781450 10.1111/j.1523-1755.2005.67109.x 10.1016/S0161-5890(03)00105-6 10.1126/science.279.5353.1052 10.1016/j.immuni.2005.02.006 10.1182/blood-2006-12-063636 10.1189/jlb.3MR0214-109R 10.3389/fimmu.2019.00504 10.1111/cei.12754
Pediatric Nephrology (Berlin, Germany); Vivarelli M, van de Kar N et. al.

May 19th, 2021 - C3 glomerulopathy is a relatively new clinical entity that represents a challenge both to diagnose and to treat. As new therapeutic agents that act as complement inhibitors become available, many with an oral formulation, a better understanding of...

see more →

Clinicaltrials.gov  3 results

Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
https://clinicaltrials.gov/ct2/show/NCT03723512

Jul 2nd, 2019 - Functional and quantitative renal magnetic resonance imaging (MRI) has seen a number of recent advances, and techniques are now available that can generate quantitative imaging biomarkers with the potential to improve the management of kidney dise...

Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
https://clinicaltrials.gov/ct2/show/NCT01221181

Feb 19th, 2019 - Dense deposit disease (DDD), also called membranoproliferative glomerulonephritis (MPGN) type II, is a rare form of glomerulonephritis named because of the characteristic appearance of electron-dense material in the glomerular basement membrane ob...

Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT03201406

Jul 2nd, 2017 - During 1993 and 2006, a total of 987 patients older than 20 years underwent native kidney biopsy at the Renal Division of this hospital. 404 patients with membranoproliferative glomerulonephritis and mesangioproliferative glomerulonephritis, and p...

see more →

News  4 results

A Rare Case of Immunotactoid Glomerulopathy and Monoclonal Gammopathy of Renal Significance due to an IgM Kappa Clone at the VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/207783/mixed-topics/rare-case-immunotactoid-glomerulopathy-and-monoclonal?channel=53
Kuang C, Alshoubaki N et. al.

Sep 9th, 2019 - Introduction: Monoclonal gammopathy of renal significance (MGRS) is a recently recognized disorder from pathologic M protein causing renal disease and minimal hematologic disease burden. Failure to treat leads to poor outcomes from progression to.

A 65-Year-Old Man With Hypertension and Proteinuria
https://reference.medscape.com/viewarticle/852384_3

Oct 12th, 2015 - On the basis of the history, physical examination, and workup, what is the diagnosis? Your Peers Chose: Diabetic kidney disease 0% Hypertensive nephrosclerosis 0% Unrecovered AKI 0% Hepatitis C-related membranoproliferative glomerulonephritis 0% D...

HCV Treatment: What Can I Do Now? What's Coming Next?
https://www.medscape.com/viewarticle/849473_4

Aug 24th, 2015 - Options for Difficult-to-Treat Patients The HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C website[16] provides recommendations for the treatment of patients with decompensated HCV cirrhosis (Child-Turcotte-Pugh clas...

Influence of Hepatitis C Virus Co-Infection and Hepatitis C Virus Treatment on Risk of Chronic Kidney Disease in HIV-Positive Persons
https://www.medscape.com/viewarticle/934434_4

Discussion This large study of almost 15 000 individuals with a median follow-up of approaching 7 years and with known anti-HCV and HCV-RNA status has found no reduction in CKD among those with cured HCV infection following treatment for HCV. To d...

see more →